Clinical Trial in Females for Female Pattern Hair Loss
Launched by JOHNSON & JOHNSON HEALTHCARE PRODUCTS DIVISION OF MCNEIL-PPC, INC. · Oct 21, 2010
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
This is a phase 3, two-arm, randomized, double-blind, vehicle-controlled, multi-center, 24-week, parallel design trial to evaluate the efficacy and safety in women with Female Pattern Hair Loss (FPHL), comparing the 5% MTF formulation versus the foam vehicle formulation.
This clinical trial is designed to compare the risk/benefit profile of the new 5% MTF formulation applied once a day (OD) versus the foam vehicle formulation applied once a day (OD), using objective efficacy measures and safety assessments.
Study centers will screen a sufficient number of participants so that a minimum of...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • females, age 18 or older in general good health
- • exhibits female pattern hair loss
- • signs and dates an informed consent document
- • agrees to use an adequate method of birth control; if of childbearing potential
- • shows a negative urine pregnancy test at Screening Visit
- • is willing to maintain the same hair style, hair color, and hair regimen throughout the study
- • is willing and able to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures
- Exclusion Criteria:
- • hypersensitivity to the (study product), or any ingredients of the (study product)
- • known allergy to hair dye, or hair dye components
- • clinically relevant history of hypotension
- • untreated or uncontrolled hypertension
- • pregnant, planning a pregnancy or nursing a child
- • history of hair transplants
- • currently use hair weaves or non-breathable wigs
- • dermatologic disorders of the scalp that require chronic use of medication for control
- • other types or history of hair loss
- • enrolled in any other investigational medication (drug) study currently, or within the last 6 months
About Johnson & Johnson Healthcare Products Division Of Mcneil Ppc, Inc.
Johnson & Johnson Healthcare Products Division of McNeil-PPC, Inc. is a leading pharmaceutical and consumer health company dedicated to improving the quality of life for individuals around the world. With a strong emphasis on innovation and safety, the division develops and markets a diverse range of healthcare products, including over-the-counter medications and wellness solutions. Committed to rigorous clinical research, McNeil-PPC actively engages in clinical trials to evaluate the efficacy and safety of its products, ensuring they meet the highest standards of quality and effectiveness. Through its dedication to advancing healthcare, Johnson & Johnson Healthcare Products Division plays a pivotal role in enhancing public health and wellbeing.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Cleveland, Ohio, United States
Fridley, Minnesota, United States
San Diego, California, United States
Nuneaton, , United Kingdom
Stony Brook, New York, United States
Clinton Township, Michigan, United States
College Station, Texas, United States
Wichita, Kansas, United States
Los Angeles, California, United States
Glenn Dale, Maryland, United States
Dallas, Texas, United States
Lynchburg, Virginia, United States
Besançon, , France
Berlin, , Germany
Freiburg, , Germany
Patients applied
Trial Officials
Clare Kendall
Study Director
Johnson & Johnson Consumer and Personal Products Worldwide
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials